** Shares of drugmaker Bristol Myers Squibb BMY.N up 3.2% at $57.61
** Co says the U.S. FDA has accepted for review its marketing application seeking approval of the combination of BMY's Opdivo plus Yervoy as a potential first-line treatment option for patients with types of colorectal cancer
** The FDA is set to make a decision by June 23
** Opdivo plus Yervoy is already approved to treat cancers of the skin, lung, kidney, colon and esophagus
** BMY has rose ~10% in the last 12 months
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。